Search results for: 'Small Molecule Contract Development and Manufacturing Organization'

This Frost Radar™ analyzes the competitive landscape of the antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) market. Companies provide the foundational manufacturing and development services for what has become one of the most dynamic and valuable therapeutic modalities in oncology. The success of the ADC rev...

The study on the "Global Biologics Contract Development & Manufacturing Organizations (CDMO) Market: Companies-to-Action" presents an overview of the global biologics development and manufacturing landscape with an emphasis on the seven leading CDMOs in the market. The study highlights the shifting focus and investments of bio-pharma companies towa...

Organic solar cells (OSCs) are emerging as one of the more versatile photovoltaic technologies inthe third-generation solar cell technology domain, owing to their unique characteristics of flexibility, ultralightweight form factors, low-temperature processing, and compatibility with high-throughput printing techniques. Advancements in donor–accepto...

17 Jun 2021  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities

Asset Co-Development with Clinical-stage Biopharmaceutical Companies and Disruptive Technologies Present Future Growth Potential

Infographics

×

This study presents Frost & Sullivans overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as...

19 Sep 2018  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022

Investments in Single Use/Disposable Technologies to Capitalize on Growth Opportunities in High-value Low-volume Biologics

Infographics

×

Key Issues Addressed

The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs are shifting from traditional small molecules to large molecules. This study presents an overview of the global b...

Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) ma...

10 Sep 2024  |  Global  |  Technology Research

Technology Advances in Modular and Automated Platforms for Pharmaceutical Manufacturing

Increasing demand for small molecule drugs is driving the growth of modular and automated technologies in pharmaceutical manufacturing

Infographics

×

This study examines technology advances in modular and automated platforms for non-biologics manufacturing in the pharmaceutical sector. There is a growing demand for automated and modular technologies that ensure regulatory compliance, increase productivity, reduce waste, and meet emerging therapeutic requirements such as those of the personalized...

The US and European mammalian contract development and manufacturing organization (CDMO) market is entering a new phase of strategic evolution, driven by accelerating biologics outsourcing, increasing molecule complexity, and growing demand for resilient, end-to-end manufacturing partnerships. As monoclonal antibodies, bispecific antibodies, Fc-fus...

With persistent geopolitical tensions and the resultant trade fragmentation continuing to shape the global economy, policy priorities among countries advanced and emerging are shifting toward macroeconomic frameworks that will insulate them from external shocks. Incremental reforms that support sustainability and Industry 5.0 practices will have pr...